Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $1.0 billion.

  • Janux Therapeutics' Liabilities and Shareholders Equity rose 4744.43% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 6977.07%. This contributed to the annual value of $1.1 billion for FY2024, which is 17904.74% up from last year.
  • Latest data reveals that Janux Therapeutics reported Liabilities and Shareholders Equity of $1.0 billion as of Q3 2025, which was up 4744.43% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Liabilities and Shareholders Equity peaked at $1.1 billion during Q4 2024, and registered a low of $341.5 million during Q2 2023.
  • Over the past 5 years, Janux Therapeutics' median Liabilities and Shareholders Equity value was $389.0 million (recorded in 2021), while the average stood at $576.0 million.
  • Per our database at Business Quant, Janux Therapeutics' Liabilities and Shareholders Equity surged by 224213.48% in 2021 and then tumbled by 1138.27% in 2023.
  • Janux Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $379.8 million in 2021, then fell by 4.16% to $364.0 million in 2022, then rose by 4.5% to $380.4 million in 2023, then soared by 179.05% to $1.1 billion in 2024, then dropped by 3.46% to $1.0 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.0 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.1 billion in Q1 2025.